MedTrace Logo

Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes

NCT00614120 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 929

Last updated 2017-03-08

Study results available
· View outcomes & findings →

Summary

This trial is conducted in Asia. The trial is designed to compare the effect on glycaemic control of liraglutide or glimepiride added to metformin in subjects with type 2 diabetes

Conditions

Interventions

DRUG

liraglutide

0.6 mg/day, s.c. (under the skin) injection

DRUG

placebo

Glimepiride placebo, capsules

DRUG

liraglutide

1.2 mg/day, s.c. (under the skin) injection

DRUG

liraglutide

1.8 mg/day, s.c. (under the skin) injection

DRUG

glimepiride

Capsules, 4.0 mg/day

DRUG

metformin

Tablets, 1.5-2.0 g/day

DRUG

placebo

Liraglutide placebo, s.c. (under the skin) injection

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452), MD, PhD · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2009-02-28
Completion
2009-02-28

Countries

  • China
  • India
  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00614120 on ClinicalTrials.gov